

Human COVID 19 Spike Coronavirus Antibody | anti-COVID-19 antibody

SARS-CoV-2 Spike Antibody (AM002414)

CATALOG #	HOST	REACTIVITY	APPLICATIONS
AAA60299	Human	Virus	ELISA, Neutralization Assay


PRODUCT SYNONYMS

COVID 19 Spike Coronavirus; SARS-CoV-2 Spike Antibody (AM002414); 2019 Novel Coronavirus; Coronavirus; CoV; COVID-19 virus; HCoV-2; Human Coronavirus 2019; SARS2; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Spike; anti-COVID-19 antibody

PRODUCT SPECIFICATIONS


Host	Human
Reactivity	Virus
Isotype	IgG1, k
Clone Number	AM002414 (414-2)
Purity/Purification	Protein A Chromatography
Form/Format	140mM Hepes, pH7.5, 70mM NaCl, 32mM NaOAc, 0.035% sodium azide, and 30% glycerol. Sodium azide is highly toxic.
Concentration	1ug/ul (varies by lot)
Applicable Applications for anti-COVID-19 antibody	ELISA, NTRL (Neutralization)
Antibody Type	Recombinant Antibody
Preparation and Storage	Some products may be shipped at room temperature. This will not affect their stability or performance. Avoid repeated freeze/thaw cycles by aliquoting items into single-use fractions for storage at -20 degree C for up to 2 years. Keep all reagents on ice when not in storage.1ug/ul

IMAGES



Application Data

SARS-CoV-2 Spike Antibody (clone AM002414) tested by Neutralization. Viral neutralization assays were performed with pseudotyped virus carrying a luciferase reporter gene and bearing the SARS-CoV-2 S1 spike glycoprotein. A549 lung epithelial target cells expressing the ACE2 receptor were incubated with virus and a graded dose of SARS-CoV-2 Spike Antibody (clone AM002414). Luciferase signal, indicative of cellular infection and viral gene expression, was measured. Viral neutralization by SARS-CoV-2 antibodies inhibits viral entry and, by extension, virus associated luciferase signal in manner proportional to antibody dose.



ELISA

SARS-CoV-2 Spike Antibody (clone AM002414) tested by ELISA. SARS-CoV-2 Spike RBD protein was coated onto microtiter plates at 0.5 ug/mL and then incubated with a dilution series of SARS-CoV-2 Spike Antibody (clone AM002414). Bound antibodies were detected with anti-human IgG conjugated to horseradish peroxidase (HRP) followed by incubation with HRP Substrate and then measuring the resulting absorbance at 450 nm.

ADDITIONAL INFORMATION

Related Product Information for anti-COVID-19 antibody	Short Description: Our SARS-CoV-2 Spike Antibody (AM002414) was raised in a Human host. It has been validated for use in Neutralizing and ELISA; it has been shown to react with Virus samples. Background: COVID-19, which is short for coronavirus disease 2019, is the official name of the respiratory disease caused by infection with the novel coronavirus SARS-CoV-2. The virus that causes COVID-19 was named SARS-CoV-2 because it is a coronavirus genetically similar to, yet distinct from, the virus that caused the severe acute respiratory syndrome (SARS) outbreak in 2003. Studying the details of how this virus replicates and causes the disease will allow scientists and physicians to more rapidly develop fast and accurate methods of detection as well as to deploy therapeutic and vaccine strategies. This antibody was derived from COVID-19 patients who have cleared the virus. Patient serum IgG was sequenced and expressed as full-length IgG1 with human immunoglobulin heavy and light chains in mammalian 293 cells.
Product Categories/Family for anti-COVID-19 antibody	Primary Antibodies

NCBI AND UNIPROT INFORMATION

UniProt Accession #	QHD43416.1
Molecular Weight	Mol_Mass: 47.9 kDa; AP_Mol_Mass: 50-60 kDa

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.

AAA Biotech | Tel: +1 (619) 604-9440 | Fax: +1 (619) 604-9441 | contact@aaabiotech.com
Online datasheet: <https://stage.aaabiotech.com/human-covid-19-antibody/covid-19-spike-coronavirus/60299>